Effects of Metformin and Vitamin D on Clinical Outcome in Cholangiocarcinoma Patients
- 24 February 2021
- journal article
- research article
- Published by S. Karger AG in Oncology
- Vol. 99 (5) , 292-299
Abstract
Background and Aims: In the last few years, there has been increasing interest in non-cancer medications and their potential anti-cancer activity. Data are not available in cholangiocarcinoma (CCA) patients. The aim of this study is to fill this gap by investigating the potential impact in terms of clinical outcome of the common non-cancer medications. Methods: All consecutive patients with CCAs were retrospectively identified from 7 Italian medical institutions. We investigated the role of intake of vitamin D, aspirin, metformin, statins, and diuretics. Results: A total of 537 patients with CCAs were identified; 197 patients undergoing surgery were evaluated for disease-free survival (DFS), and 509 patients with an advanced stage were evaluated for overall survival (OS). A longer DFS was found in patients with intake of vitamin D versus never users (HR 0.55, 95% CI 0.32–0.92, p = 0.02). In an advanced stage an association with OS was found in patients with intake of metformin versus never users (HR 0.70, 95% CI 0.52–0.93, p = 0.0162), and in patients who have started taking metformin after chemotherapy versus before chemotherapy and never users (HR 0.44, 95% CI 0.26–0.73, p = 0.0016). Conclusions: Our results highlighted that vitamin D intake improves DFS in patients undergoing surgery. Metformin intake after starting chemotherapy can improve the clinical outcome in advanced disease. These results could open up new therapeutic strategies in cholangiocarcinoma patients. We are planning to undertake a prospective study to validate these data.Keywords
This publication has 33 references indexed in Scilit:
- The role of vitamin D in reducing cancer risk and progressionNature Reviews Cancer, 2014
- Metformin Therapy and Risk of Cancer in Patients with Type 2 Diabetes: Systematic ReviewPLOS ONE, 2013
- Association of metformin use with cancer incidence and mortality: A meta-analysisCancer Epidemiology, 2013
- Aspirin Use, TumorPIK3CAMutation, and Colorectal-Cancer SurvivalNew England Journal of Medicine, 2012
- Risk Factors for Intrahepatic Cholangiocarcinoma: Association Between Metformin Use and Reduced Cancer RiskHepatology, 2012
- Aspirin acetylates multiple cellular proteins in HCT-116 colon cancer cells: Identification of novel targetsInternational Journal of Oncology, 2011
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract CancerNew England Journal of Medicine, 2010
- Aspirin inhibits camptothecin-induced p21CIP1 levels and potentiates apoptosis in human breast cancer cellsInternational Journal of Oncology, 2009
- Aspirin Sensitizes Cancer Cells to TRAIL–Induced Apoptosis by Reducing Survivin LevelsClinical Cancer Research, 2008
- Overexpression of vitamin D receptor indicates a good prognosis for cholangiocarcinomaCancer, 2007